"The launch of the generic versions of Axiron® made it no longer commercially viable to market Axiron® in the US, and the product was withdrawn from the US market on 5th September 2017"
so I guess reducing the price and meeting the challenge of the generics headon was not an option??. more to this then meets the eye IMO - wonder if condition of Eli agreement dissolution was that ACR was unable to market its product in a generic form??
transparency just like the Hexima matter hey!!!
- Forums
- ASX - By Stock
- ACR
- Ann: Axiron Patents Appeal Decision
Ann: Axiron Patents Appeal Decision, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.89M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3903 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3903 | 0.062 |
2 | 116666 | 0.060 |
1 | 17200 | 0.058 |
2 | 167543 | 0.057 |
2 | 67857 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 100000 | 1 |
0.065 | 70395 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 30000 | 3 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
Day chart unavailable